ArticleFrontiers in immunology2026
M2-type tumor-associated macrophages promote invasion of canine breast cancer through ADAM9 upregulation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumor-associated macrophages (TAMs) represent the most abundant immune cell population within the tumor microenvironment and play a critical role in cancer progression. However, the molecular mediators underlying TAM-driven tumor invasion remain incompletely defined. This study investigated whether ADAM9 functions as a key effector of pro-invasive TAM polarization using a canine mammary tumor model integrated with human transcriptomic datasets. Methods: Transcriptomic analyses were performed using canine and publicly available human datasets. Single-cell RNA sequencing was used to determine cellular localization of ADAM9. IL-4-induced M2 macrophages were evaluated for ADAM9 expression, tumor migration and invasion capacity, extracellular matrix (ECM) degradation, cytoskeletal remodeling, and spheroid destabilization. ADAM9 knockdown and cancer stem cell (CSC)-conditioned medium experiments were conducted to assess mechanistic involvement. Results: ADAM9 was consistently enriched in M2-polarized TAMs across species and was confirmed to be expressed in TAM populations by single-cell RNA sequencing. IL-4-induced M2 macrophages upregulated ADAM9 and significantly enhanced tumor migration and invasion. ADAM9 knockdown attenuated ECM degradation, reduced MMP9 expression, and disrupted F-actin remodeling. CSC-conditioned medium further induced ADAM9 expression, suggesting its role as a convergent mediator of CSC-macrophage crosstalk. In spheroid models, ADAM9 depletion prevented TAM-mediated spheroid destabilization and suppressed collective invasion. Conclusion: These findings identify ADAM9 as a key effector of TAM-driven tumor invasion through ECM remodeling and cytoskeletal regulation, and highlight ADAM9 as a promising therapeutic target within the tumor immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.